The Co-Pilot showed sustained virological response at 12 weeks post treatment (SVR12) in 95% and 93% of treatment-naïve genotype 1 (GT1) patients.
In these patients, response was independent of HCV subtype, host IL28B genotype or dose of ABT-450/r.
The Pilot study showed 91% of genotype 1 infected, treatment-naïve patients taking ABT-450/r and ABT-072 combined with ribavirin administered for 12 weeks, achieved sustained viral response at 24 weeks (SVR24).
Abbott infectious disease development divisional vice president Scott Brun said: "The data suggest that with a 12-week regimen containing just two of our direct-acting antiviral medicines, and no peginterferon, we can achieve high cure rates in treatment-naïve, genotype 1 patients."